Literature DB >> 17602291

Selective segmental ostial ablation and circumferential pulmonary veins ablation. Results of an individualized strategy to cure refractory atrial fibrillation.

David Tamborero1, Lluis Mont, Irma Molina, Maria Matiello, Antonio Berruezo, Marta Sitges, Rosario Jesús Perea, Teresa M de Caralt, Barbara Vidal, Nibaldo Zamorano, Josep Brugada.   

Abstract

AIMS: Previous studies have analyzed the efficacy of atrial fibrillation (AF) ablation in series of consecutive patients or comparing methods in a randomized way, without taking account individual patient characteristics. The purpose of this study was to evaluate the results of a strategy based on selecting the ablation method according to patient clinical features in drug-refractory paroxysmal or persistent AF. METHODS AND
RESULTS: Patients with left atrial diameter < or =40 mm and runs of atrial tachycardia of more than ten beats during Holter recording were selected for selective segmental ostial ablation (SSOA) in order to disconnect only those pulmonary veins with electrical potentials. The remaining patients underwent circumferential pulmonary veins ablation (CPVA) to modify left atrial substrate by extensive linear lesions. A group of 131 consecutive patients were included. Mean follow-up was 21.5 +/- 15.2 months. In paroxysmal AF, 44 and 55 patients were selected for SSOA and CPVA, respectively, and the efficacy of the procedure was similar in the two groups (77 vs 74%; log-rank test p = NS). In persistent AF, 6 and 26 patients underwent SSOA and CPVA, respectively, and greater efficacy was observed in the second group (17 vs 65%; log-rank test p = 0.004).
CONCLUSIONS: Selecting the ablation method according to patient characteristics achieved good results and reduced the overall amount of ablated atrial tissue in patients with paroxysmal AF. However, in persistent AF the SSOA technique showed very limited efficacy despite the previous patient selection and a CPVA-like procedure may be the appropriate choice in all cases.

Entities:  

Mesh:

Year:  2007        PMID: 17602291     DOI: 10.1007/s10840-007-9129-6

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  32 in total

1.  Substrate modification combined with pulmonary vein isolation improves outcome of catheter ablation in patients with persistent atrial fibrillation: a prospective randomized comparison.

Authors:  Stephan Willems; Hanno Klemm; Thomas Rostock; Benedikt Brandstrup; Rodolfo Ventura; Daniel Steven; Tim Risius; Boris Lutomsky; Thomas Meinertz
Journal:  Eur Heart J       Date:  2006-06-16       Impact factor: 29.983

2.  Prevention of iatrogenic atrial tachycardia after ablation of atrial fibrillation: a prospective randomized study comparing circumferential pulmonary vein ablation with a modified approach.

Authors:  Carlo Pappone; Francesco Manguso; Gabriele Vicedomini; Filippo Gugliotta; Ornella Santinelli; Amedeo Ferro; Simone Gulletta; Simone Sala; Nicoleta Sora; Gabriele Paglino; Giuseppe Augello; Eustachio Agricola; Alberto Zangrillo; Ottavio Alfieri; Vincenzo Santinelli
Journal:  Circulation       Date:  2004-11-01       Impact factor: 29.690

3.  Electrophysiological breakthroughs from the left atrium to the pulmonary veins.

Authors:  M Haïssaguerre; D C Shah; P Jaïs; M Hocini; T Yamane; I Deisenhofer; M Chauvin; S Garrigue; J Clémenty
Journal:  Circulation       Date:  2000-11-14       Impact factor: 29.690

4.  Long-term evaluation of atrial fibrillation ablation guided by noninducibility.

Authors:  Pierre Jaïs; Mélèze Hocini; Prashanthan Sanders; Li-Fern Hsu; Yoshihide Takahashi; Martin Rotter; Thomas Rostock; Frédéric Sacher; Jacques Clementy; Michel Haissaguerre
Journal:  Heart Rhythm       Date:  2006-02       Impact factor: 6.343

5.  Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation.

Authors:  Hakan Oral; Bradley P Knight; Hiroshi Tada; Mehmet Ozaydin; Aman Chugh; Sohail Hassan; Christoph Scharf; Steve W K Lai; Radmira Greenstein; Frank Pelosi; S Adam Strickberger; Fred Morady
Journal:  Circulation       Date:  2002-03-05       Impact factor: 29.690

6.  Catheter ablation for paroxysmal atrial fibrillation: segmental pulmonary vein ostial ablation versus left atrial ablation.

Authors:  Hakan Oral; Christoph Scharf; Aman Chugh; Burr Hall; Peter Cheung; Eric Good; Srikar Veerareddy; Frank Pelosi; Fred Morady
Journal:  Circulation       Date:  2003-10-13       Impact factor: 29.690

Review 7.  Rotors and spiral waves in atrial fibrillation.

Authors:  José Jalife
Journal:  J Cardiovasc Electrophysiol       Date:  2003-07

8.  Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study.

Authors:  Carlo Pappone; Salvatore Rosanio; Giuseppe Augello; Giuseppe Gallus; Gabriele Vicedomini; Patrizio Mazzone; Simone Gulletta; Filippo Gugliotta; Alessia Pappone; Vincenzo Santinelli; Valter Tortoriello; Simone Sala; Alberto Zangrillo; Giuseppe Crescenzi; Stefano Benussi; Ottavio Alfieri
Journal:  J Am Coll Cardiol       Date:  2003-07-16       Impact factor: 24.094

9.  Pulmonary vein stenosis after catheter ablation of atrial fibrillation: emergence of a new clinical syndrome.

Authors:  Eduardo B Saad; Nassir F Marrouche; Cynthia P Saad; Edward Ha; Dianna Bash; Richard D White; John Rhodes; Lourdes Prieto; David O Martin; Walid I Saliba; Robert A Schweikert; Andrea Natale
Journal:  Ann Intern Med       Date:  2003-04-15       Impact factor: 25.391

Review 10.  Mother rotors and fibrillatory conduction: a mechanism of atrial fibrillation.

Authors:  José Jalife; Omer Berenfeld; Moussa Mansour
Journal:  Cardiovasc Res       Date:  2002-05       Impact factor: 10.787

View more
  1 in total

1.  Benefit of left atrial roof linear ablation in paroxysmal atrial fibrillation: a prospective, randomized study.

Authors:  Elena Arbelo; Esther Guiu; Pablo Ramos; Felipe Bisbal; Roger Borras; David Andreu; José María Tolosana; Antonio Berruezo; Josep Brugada; Lluís Mont
Journal:  J Am Heart Assoc       Date:  2014-09-05       Impact factor: 5.501

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.